Retatrutide and Lean Mass Loss

Three things are true at once and most pages on this topic only carry one of them. Retatrutide produced large, dose-related reductions in total fat mass in the one trial that scanned people. Lean mass came down alongside it, because lean mass comes down alongside every substantial weight loss ever measured. And the published verdict on retatrutide is not that it spares lean tissue unusually well, it is that the proportion of lean loss looked comparable to other obesity treatments.

That third sentence is the one the SERP is missing. It is less exciting than either the marketing version or the scare version, and it is what the data says.

The dataset is a body composition substudy of the Phase 2 retatrutide trial in adults with type 2 diabetes, published in The Lancet Diabetes and Endocrinology in August 2025. It ran across 42 US medical centres inside the parent trial, which was a double-blind, parallel-group, placebo-controlled and active-controlled randomised study.

The design detail that governs how much weight to put on it: 189 participants entered the substudy and 103 completed treatment with both a baseline and a week 36 DXA scan. Those 103 were then split across six arms. Placebo, dulaglutide 1.5mg as an active comparator, and retatrutide at 0.5mg, 4mg pooled across its escalation routes, 8mg pooled, and 12mg. Divide 103 across six arms and the per-arm denominators are small.

Two more framing facts. The population was people with type 2 diabetes with a BMI between roughly 25 and 50, not the general obesity population of the pivotal trial. And the observation window was 36 weeks, which is less than half the length of TRIUMPH-1. Body composition is not static across a weight loss curve, and 36 weeks catches it mid-descent.

Percent reduction from baseline in total fat mass at week 36, as reported. Standard errors are given where the publication gives them.

The two significant comparisons against placebo were 21.6 percentage points at 8mg, with a 95% confidence interval of 27.1 to 16.1, and 18.7 percentage points at 12mg, with a 95% confidence interval of 25.1 to 12.3. Both at p below 0.0001. Those are large effects on adipose tissue, and they are the headline of the paper.

Read the placebo row before the drug rows. Placebo lost 4.5% of fat mass over 36 weeks, which is what happens when people enrol in a trial, get monitored and pay attention to what they eat. The 0.5mg retatrutide arm, at 4.9%, is indistinguishable from it. The dose effect does not begin until 4mg.

The 8mg arm shows a bigger fat mass reduction than the 12mg arm: 26.1% against 23.2%. Several pages have picked that up and run with it as though it proved something about an optimal dose. It does not.

With 103 completers across six arms, each arm holds somewhere in the region of a dozen to twenty people. The reported standard errors of 2.5% and 3.0% around those two means overlap comfortably. In a sample that size, an inversion of three percentage points between adjacent dose arms is the ordinary behaviour of small numbers, not a signal. The parent trial and the entire Phase 3 programme show clean, monotonic dose response on total body weight, and there is no mechanistic reason to expect adipose tissue to behave differently.

There is a second reason not to build anything on it. 8mg is a Phase 2 dose that the Phase 3 programme dropped. TRIUMPH-1 tested 4mg, 9mg and 12mg. Anyone reasoning from the substudy toward a dose choice is reasoning toward a rung that no longer exists on the ladder, which is covered in the titration filing.

This is where the page has to be careful, because it is where every other page stops being careful.

The substudy reports fat mass as its headline output. On lean tissue, its conclusion is stated in proportional terms: retatrutide significantly improved total body fat mass reduction while the proportion of lean mass loss relative to total weight loss was comparable to other obesity treatments. That is the finding. It is a comparability claim, not a preservation claim.

What follows from it matters. It means the honest reading of retatrutide on lean tissue is neutral. The compound produces more total weight loss than the drugs it is being compared with, so in kilograms it will take more lean tissue with it, and as a share of the total it landed in the same territory as its class. Anyone writing that retatrutide is muscle-sparing is claiming something the substudy did not report. Anyone writing that it is unusually catabolic is claiming the opposite, and the substudy did not report that either.

To judge whether a lean mass number is good or bad you need to know what normal looks like. Two reference points make that possible, and neither is about retatrutide.

The first is the SURMOUNT-1 body composition substudy of tirzepatide, published in Diabetes, Obesity and Metabolism in 2025. It scanned 160 participants, 124 on pooled tirzepatide doses and 36 on placebo, at 72 weeks. Total body weight fell 21.3% on tirzepatide, total fat mass fell 33.9% and lean mass fell 10.9%. On placebo the same three figures were 5.3%, 8.2% and 2.6%. All significant at p below 0.001.

The line worth memorising from that paper is what those figures resolve to: roughly 75% of the weight lost was fat mass and roughly 25% was lean mass, in both the drug group and the placebo group. The drug moved the size of the loss. It did not move the split.

The second reference point is older and broader. A quarter of weight lost being fat-free mass has been a working rule in obesity research for decades. Heymsfield and colleagues examined it directly in Obesity Reviews in 2014, under the title that gives the rule its name, and their conclusion was that it is a reasonable central estimate rather than a constant. The share moves with the size of the energy deficit, with how much fat a person started with, and with what they were doing physically during the loss. Larger deficits and lower starting adiposity both push the fat-free share up.

n/r means not reported in the published abstract for that arm. The two datasets ran in different populations over different durations with different scan protocols, so the rows sit side by side for orientation and not as a head to head comparison.

Take two hypothetical people who both start at 100kg. One loses 15kg and one loses 28kg. At a 75 to 25 split, the first loses about 3.75kg of lean tissue and the second about 7kg. The second person has lost nearly twice as much lean tissue in kilograms, and the two of them have identical body composition outcomes in every sense that matters.

That arithmetic is why absolute lean mass figures are the wrong instrument for comparing compounds. A more effective drug will always look worse on the absolute number, purely because it produced more weight loss. The comparison only becomes informative when it is normalised, which is exactly why the retatrutide substudy phrased its conclusion as a proportion and why the SURMOUNT-1 authors reported theirs the same way.

There is a second reason the proportion is the better lens. Lean mass in a heavier body is partly structural. Carrying 130kg requires more skeletal muscle than carrying 95kg, and some of the lean tissue lost during a large weight reduction is muscle that existed to move the mass that is no longer there. Reduction in that tissue is a consequence of the change rather than a deficit, and an absolute-kilogram framing cannot tell the two apart.

None of which makes lean loss trivial. A 25% lean share of a 28% body weight reduction is a substantial amount of tissue in anyone. It is the reason the research literature on this class has moved toward measuring function and not only mass.

Being explicit about the limits is more useful than filling them in.

Lean mass is not muscle. The DXA lean compartment includes skeletal muscle, organs, connective tissue and water. Glycogen depletion alone moves it, because each gram of stored glycogen is bound to several grams of water. Early lean mass readings in any weight loss study partly record fluid shifts rather than tissue.

Mass is not function. Neither dataset on this page measured grip strength, gait speed, leg extension power or any other functional endpoint. A change in the lean compartment and a change in what a person can physically do are different measurements, and the second is what actually matters.

36 weeks is not a plateau. The retatrutide substudy scanned mid-descent. Body composition trajectories are not linear, and the picture at week 36 in a Phase 2 trial says little about week 80 in a Phase 3 one.

The population was type 2 diabetes. Baseline body composition, insulin status and drug response differ between people with type 2 diabetes and the general obesity population that TRIUMPH-1 enrolled. The substudy result does not transfer cleanly.

And there is no Phase 3 body composition data at all. The efficacy record has moved a long way since Phase 2, with 28.3% at 80 weeks in TRIUMPH-1 and 30.3% in the 104-week extension, all set out in the Phase 3 results filing. The body composition record has not moved at all.

Across the obesity research literature, and not specific to this compound, three variables come up repeatedly as the ones associated with the fat to lean split rather than with the size of the loss. They are the rate of loss, protein intake and resistance training. Heymsfield and colleagues identified the magnitude of the energy deficit as one of the factors that moves the fat-free share, and the training and protein literature in weight reduction is long-standing and independent of any drug.

That is reported here as what the literature discusses, not as instruction. No retatrutide trial randomised participants to different protein intakes or training programmes, so there is no retatrutide-specific evidence on any of it, and nothing on this page is a recommendation about diet, training or dosing.

The regulatory position frames all of it. Retatrutide is not approved in any market and is not registered with FDA Philippines. Lilly stated in July 2026 that it plans to submit a Biologics License Application to the US FDA in Q1 2027. In this country the compound exists as research material, which is the subject of the retatrutide Philippines filing, with the regulatory background in the FDA Philippines guide.

1. [01]SubstudyLancet Diabetes Endocrinol 2025 · Retatrutide body composition substudy

   Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol 2025;13(8):674-684. Source for the week 36 fat mass figures, the arm structure, the 103 DXA completers and the proportional lean mass conclusion.

   pubmed.ncbi.nlm.nih.gov/40609566
2. [02]SubstudyDiabetes Obes Metab 2025 · SURMOUNT-1 body composition

   Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study. Diabetes Obes Metab 2025;27(5):2720-2729. Source for the 75% fat and 25% lean split, and the -21.3% weight, -33.9% fat, -10.9% lean figures at 72 weeks.

   pubmed.ncbi.nlm.nih.gov/39996356
3. [03]ReviewObesity Reviews 2014 · The one-fourth fat-free mass rule

   Heymsfield SB et al. Weight loss composition is one-fourth fat-free mass: a critical review and critique of this widely cited rule. Obes Rev 2014;15(4):310-321. Source for the rule itself and for the finding that the fat-free share varies with energy deficit, baseline adiposity and activity.

   pubmed.ncbi.nlm.nih.gov/24447775
4. [04]TrialLilly · TRIUMPH-1 readout, 21 May 2026

   The pivotal obesity trial, n=2,339 over 80 weeks. Source for 19.0%, 25.9% and 28.3% by dose, the 30.3% 104-week extension figure, and confirmation that no body composition endpoints were reported.

   investor.lilly.com · TRIUMPH-1 release
5. [05]TrialNEJM 2023 · Retatrutide Phase 2 obesity trial

   Jastreboff AM et al. N Engl J Med 2023;389:514-526. The Phase 2 obesity trial, n=338 over 48 weeks, 24.2% at 12mg. Context for the Phase 2 dose ladder that included 8mg.

   nejm.org · 10.1056/NEJMoa2301972